Weekly injectable buprenorphine is more effective than daily doses for treating opioid use disorder in pregnancy, with higher ...

Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more ...

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder ...

Suboxone is now the standard of care in the U.S. for treating opioid addiction, but its downsides are often overlooked. RFK ...

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release ...

More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

Use of medications for newly-diagnosed opioid use disorder (OUD) increased from 2016 to 2019 but remained low, a new cohort study showed. Additionally, methadone and buprenorphine were potentially ...

The risk of congenital malformations appears to be lower with buprenorphine than with methadone when taken during the first trimester of pregnancy for opioid use disorder (OUD), according to an ...

More than 15 years ago, Yale’s Gail D’Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

Last year the U.S. had about 81,000 overdose deaths involving opioids. The tally since 1999 is at least 645,000. Though the culprits have changed over the years—first it was prescription opioids, then ...

Nearly all Americans are aware of the U.S. opioid crisis. Overdose deaths increased sixfold between 2003 and 2023, from 12,940 to 79,358. Yearly increases have been especially steep since 2013, when ...

The US Food and Drug Administration (FDA) is urging manufacturers to revise labeling of transmucosal buprenorphine products to ease access to higher doses needed due to the rise of high-potency ...